GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China

Stock News

Apr 17

On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177937236"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177937236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177937236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177937236","market":"fut","top_or_hot":-1,"title":"GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China","media":"Stock News","content":"<p>On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-17 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1177937236","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177937236","pubTimestamp":1776415459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSKH":"GSK plc ADRhedged","BK4588":"碎股","IPOS":"Renaissance International IPO ETF","BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克"},"translate_title":"葛兰素史克Belantamab Mafodotin在中国获上市批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":1,"GSK":1,"IPOS":1,"GSK.UK":1},"content_text":"On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}